[
1. Bianco R, Gelardi T, Damiano V, Ciardiello F, Tortora G. Rational bases for the development of EGFR inhibitors for cancer treatment. Int J Biochem CellBiol 2007; 39: 1416-31.10.1016/j.biocel.2007.05.008
]Search in Google Scholar
[
2. Downward J, Yarden Y, Mayes E, Scrace G, Totty N, Stockwell P, et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 1984; 307: 521-7.10.1038/307521a0
]Search in Google Scholar
[
3. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37(Suppl 4): S9-15.10.1016/S0959-8049(01)00231-3
]Search in Google Scholar
[
4. Shelton JG, Steelman LS, Abrams SL, Bertrand FE, Franklin RA, McMahon M, et al. The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what’s genetics got to do with it? Expert Opin Ther Targets 2005; 9: 1009-30.
]Search in Google Scholar
[
5. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat RevMol Cell Biol 2001; 2: 127-37.10.1038/3505207311252954
]Search in Google Scholar
[
6. Rebersek M, Boc M, Cerkovnik P, Benedik J, Hlebanja Z, Volk N, Novakovic S, Ocvirk J. Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer - a single institution retrospective analysis. Radiol Oncol 2011; 45: 285-91.10.2478/v10019-011-0039-y342375722933967
]Search in Google Scholar
[
7. Jia Y, Lacouture ME, Su X, Wu S. Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis. J Support Oncol 2009; 7: 211-7.
]Search in Google Scholar
[
8. Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007; 12: 610-21.10.1634/theoncologist.12-5-61017522250
]Search in Google Scholar
[
9. Melosky B, Burkes R, Rayson D, Alcindor T, Shear N, Lacouture M. Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. CurrOncol 2009; 16: 16-26.10.3747/co.v16i1.361264462819229368
]Search in Google Scholar
[
10. Perez-Soler R, Delord JP, Halpern A, Kelly K, Krueger J, Sureda BM, et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005; 10: 345-56.10.1634/theoncologist.10-5-34515851793
]Search in Google Scholar
[
11. Saif MW, Kim R. Incidence and management of cutaneous toxicities associated with cetuximab. Expert Opin Drug Saf 2007; 6: 175-82.10.1517/14740338.6.2.17517367263
]Search in Google Scholar
[
12. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16: 1425-33.10.1093/annonc/mdi27916012181
]Search in Google Scholar
[
13. Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006; 55: 657-70.10.1016/j.jaad.2005.10.010
]Search in Google Scholar
[
14. Ehmann LM, Ruzicka T, Wollenberg A. Cutaneous side-effects of EGFR inhibitors and their management. Skin Therapy Lett 2011; 16: 1-3.
]Search in Google Scholar
[
15. Eilers RE Jr, Gandhi M, Patel JD, Mulcahy MF, Agulnik M, Hensing T, et al. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst 2010; 102: 47-53.10.1093/jnci/djp439
]Search in Google Scholar
[
16. Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28: 1351-7.10.1200/JCO.2008.21.7828
]Search in Google Scholar
[
17. Oslo A, Mateurs C, Soria JC, Smith A. Cutaneous side effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. Br JDermatol 2009; 161: 515-21.10.1111/j.1365-2133.2009.09214.x
]Search in Google Scholar
[
18. Lacouture M. The growing importance of skin toxicity in EGFR inhibitor therapy. Oncology (Williston Park) 2009; 23: 194-6.
]Search in Google Scholar
[
19. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6: 491-500.10.1016/S1470-2045(05)70243-6
]Search in Google Scholar
[
20. Peeters M, Price T, Van Laethem JL. Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today? Oncologist 2009; 14: 29-39.
]Search in Google Scholar
[
21. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005; 23: 5235-46.
]Search in Google Scholar
[
22. Racca P, Fanchini L, Caliendo V, Ritorto G, Evangelista W, Volpatto R, et al. Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: outcomes from an oncologic/dermatologic cooperation. ClinColorectal Cancer 2008; 7: 48-54.10.3816/CCC.2008.n.00718279577
]Search in Google Scholar
[
23. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-8.10.1200/JCO.2004.10.18214993230
]Search in Google Scholar
[
24. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007; 13: 3913-21.10.1158/1078-0432.CCR-06-261017606725
]Search in Google Scholar
[
25. Kovac V, Smrdel U. Meta-analyses of clinical trials in patients with non-small cell lung cancer. Minireview. Neoplasma 2004; 51: 334˝1-40.
]Search in Google Scholar
[
26. Potthoff K, Hofheinz R, Hassel JC, Volkenandt M, Lordick F, Hartmann JT, et al. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol 2011; 22: 524-35.10.1093/annonc/mdq38720709812
]Search in Google Scholar
[
27. Wollenberg A, Moosmann N, Klein E, Katzer K. A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition. Exp Dermatol 2008; 17: 790-2.10.1111/j.1600-0625.2008.00715.x18503553
]Search in Google Scholar
[
28. Lacouture ME, Maitland ML, Segaert S, Setser A, Baran R, Fox LP, et al. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 2010; 18: 509-22.10.1007/s00520-009-0744-x20145956
]Search in Google Scholar
[
29. Hassel JC, Kripp M, Al-Batran S, Hofheinz RD. Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists. Onkologie 2010; 33: 94-8.10.1159/00027765620215799
]Search in Google Scholar
[
30. Bernier J, Bonner J, Vermorken JB, Bensadoun RJ, Dummer R, Giralt J, et al. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2008; 19: 142-9.10.1093/annonc/mdm40017785763
]Search in Google Scholar
[
31. Lacouture ME. Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer. CancerNurs 2007; 30(4 Suppl 1): S17-26.10.1097/01.NCC.0000281758.85704.9b17666987
]Search in Google Scholar
[
32. Segaert S, Van Cutsem E. Clinical management of EGFRI dermatologic toxicities: the European perspective. Oncology (Williston Park) 2007; 21: 22-6.
]Search in Google Scholar
[
33. Galimont-Collen AF, Vos LE, Lavrijsen AP, Ouwerkerk J, Gelderblom H. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer 2007; 43: 845-51.10.1016/j.ejca.2006.11.01617289377
]Search in Google Scholar
[
34. Segaert S, Tabernero J, Chosidow O, Dirschka T, Elsner J, Mancini L, et al. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges 2005; 3: 599-606.10.1111/j.1610-0387.2005.05058.x16033478
]Search in Google Scholar
[
35. Bernier J, Russi EG, Homey B, Merlano MC, Mesia R, Peyrade F, et al. Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines. Ann Oncol 2011; 22: 2191-200.10.1093/annonc/mdr13921606209
]Search in Google Scholar
[
36. Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 2007; 56: 317-26.10.1016/j.jaad.2006.09.00517141360
]Search in Google Scholar
[
37. Tsimboukis S, Merikas I, Karapanagiotou EM, Saif MW, Syrigos KN. Erlotinibinduced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management. Clin Lung Cancer 2009; 10: 106-11.10.3816/CLC.2009.n.01319362953
]Search in Google Scholar
[
38. Wu PA, Balagula Y, Lacouture ME, Anadkat MJ. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors. Curr Opin Oncol 2011; 23: 343-51.10.1097/CCO.0b013e328347406321537180
]Search in Google Scholar
[
39. Jatoi A. Sunshine and rash: testing the role of sunscreen to prevent epidermal growth factor receptor inhibitor-induced rash. Support Cancer Ther 2007; 4: 198-202.10.3816/SCT.2007.n.01518632517
]Search in Google Scholar
[
40. Jatoi A, Thrower A, Sloan JA, Flynn PJ, Wentworth-Hartung NL, Dakhil SR, et al. Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4). Oncologist 2010; 15: 1016-22.10.1634/theoncologist.2010-0082322804320798191
]Search in Google Scholar
[
41. Jatoi A, Rowland K, Sloan JA, Gross HM, Fishkin PA, Kahanic SP, et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 2008;113: 847-53.10.1002/cncr.23621391816618543329
]Search in Google Scholar
[
42. Jatoi A, Dakhil SR, Sloan JA, Kugler JW, Rowland KM Jr, Schaefer PL, et al. Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB). SupportCare Cancer 2011; 19: 1601-7.10.1007/s00520-010-0988-5393579720820817
]Search in Google Scholar
[
43. Scope A, Agero AL, Dusza SW, Myskowski PL, Lieb JA, Saltz L, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007; 25: 5390-6.10.1200/JCO.2007.12.698718048820
]Search in Google Scholar
[
44. Deplanque G, Chavaillon J, Vergnenegre A, Falchero L. CYTAR: A randomized clinical trial evaluating the preventive effect of doxycycline on erlotinibinduced folliculitis in non-small cell lung cancer patients [Abstract]. J ClinOncol 2010; 28: Abstract 9019.10.1200/jco.2010.28.15_suppl.9019
]Search in Google Scholar
[
45. Scope A, Lieb JA, Dusza SW, Phelan DL, Myskowski PL, Saltz L, et al. A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption. J Am Acad Dermatol 2009; 61: 614-20.10.1016/j.jaad.2009.03.04619646778
]Search in Google Scholar
[
46. Fernandez-Guarino M, Perez Garcia B, Aldanondo Fernandez de la Mora I, Garcia-Millan C, Garrido Lopez P, Jaen Olasolo P. [Treatment of acneiform rash by epidermal growth factor inhibitors with oral tetracyclines]. [Spanish]. Actas Dermosifiliogr 2006; 97: 503-8.
]Search in Google Scholar
[
47. Micantonio T, Fargnoli MC, Ricevuto E, Ficorella C, Marchetti P, Peris K. Efficacy of treatment with tetracyclines to prevent acneiform eruption secondary to cetuximab therapy. Arch Dermatol 2005; 141: 1173-4.10.1001/archderm.141.9.117316172328
]Search in Google Scholar
[
48. Molinari E, De Quatrebarbes J, Andre T, Aractingi S. Cetuximab-induced acne. Dermatology 2005; 211: 330-3.10.1159/00008850216286741
]Search in Google Scholar
[
49. Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. JCutan Med Surg 2001; 5: 105-10.10.1177/120347540100500202
]Search in Google Scholar
[
50. Mitchell E, Lacouture M, Shearer H, Iannotti N. Final STEPP results of prophylactic versus reactive skin toxicity (ST) treatment (tx) for panitumumab (pmab)-related ST in patients (pts) with metastatic colorectal cancer (mCRC) [Abstract]. J Clin Oncol 2009; 27: Abstract CRA4027.10.1200/jco.2009.27.18_suppl.cra4027
]Search in Google Scholar
[
51. Hedges LV, Olkin I. Statistical methods for meta-analysis. Orlando: Academic Press; 1985.
]Search in Google Scholar
[
52. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982; 38: 963-74.10.2307/2529876
]Search in Google Scholar
[
53. Luu M, Lai SE, Patel J, Guitart J, Lacouture ME. Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib. PhotodermatolPhotoimmunol Photomed 2007; 23: 42-5.10.1111/j.1600-0781.2007.00273.x17254038
]Search in Google Scholar
[
54. Segaert S, Simonart T. The epidermal vitamin D system and innate immunity: some more light shed on this unique photoendocrine system? Dermatology 2008; 217: 7-11.
]Search in Google Scholar
[
55. Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 2009; 4: 107-19.10.1007/s11523-009-0114-019452131
]Search in Google Scholar
[
56. Perez-Soler R, Zou Y, Li T, Ling Y. Steroids and immunosuppressive agents potentiate the cytotoxicity of the EGFR inhibitor erlotinib (E) in human skin keratinocytes whereas Vit K3 exerts a protective effect: implications for the management of the skin rash [Abstract]. J Clin Oncol 2007; 25: Abstract 9124.10.1200/jco.2007.25.18_suppl.9124
]Search in Google Scholar
[
57. Perez-Soler R, Zou Y, Li T, Tornos C, Ling Y. Topical vitamin K3 (Vit K3, Menadione) prevents erlotinib and cetuximab-induced EGFR inhibition in the skin [Abstract]. J Clin Oncol 2006; 23: Abstract 3036.10.1200/jco.2006.24.18_suppl.3036
]Search in Google Scholar
[
58. Ocvirk J, Rebersek M. Management of cutaneous side effects of cetuximab therapy with vitamin K1 creme. Radiol Oncol 2008; 42: 215-24.10.2478/v10019-008-0022-4
]Search in Google Scholar
[
59. Ocvirk J, Rebersek M. Topical application of vitamin K1 cream for cetuximabrelated skin toxicities [Abstract]. Ann Oncol 2009; 20: Abstract PD-0021.
]Search in Google Scholar
[
60. Pinto C, Barone C, Martoni A, Di Tullio P, Di Fabio F, Cassano A. Vitamin K1 cream in the management of skin rash during anti-EGFR monocloncal antibody (mAb) treatment in patients with metastatic cancer: first analysis of an observational Italian study [Abstract]. J Clin Oncol 2011; 29: Abstract 594.10.1200/jco.2011.29.4_suppl.594
]Search in Google Scholar
[
61. Ocvirk J, Rebersek M, Boc M, Mesti T, Ebert M. Prophylactic use of K1 cream for reducing skin toxicity during cetuximab treatment in patients with metastatic colorectal cancer (mCRC) [Abstract]. J Clin Oncol 2010; 28: Abstract e14011.10.1200/jco.2010.28.15_suppl.e14011
]Search in Google Scholar
[
62. Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 2011; 19: 1079-95.10.1007/s00520-011-1197-6312870021630130
]Search in Google Scholar
[
63. Potthoff K, Hassel JC, Wollenberg A. Therapie und prophylaxe EGFRinhibitor- induzierter hautreaktionen. Arzneimitteltherapie 2010; 28: 191-8.
]Search in Google Scholar
[
64. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28: 4706-13.10.1200/JCO.2009.27.605520921462
]Search in Google Scholar
[
65. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28: 4697-705.10.1200/JCO.2009.27.486020921465
]Search in Google Scholar
[
66. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-71.10.1200/JCO.2008.20.839719114683
]Search in Google Scholar
[
67. Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-9.10.1200/JCO.2010.33.509121502544
]Search in Google Scholar
